When was Ensoma founded?

Ensoma was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Ensoma located?

Ensoma is headquartered in Boston, United States. It is registered at Boston (United States).

How many employees does Ensoma have?

As of Apr 30, 2026, the latest employee count at Ensoma is 57.

Is Ensoma a funded company?

Ensoma is a funded company, having raised a total of $205M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 11, 2021.

When was the latest funding round of Ensoma?

Ensoma's latest funding was a $***** Series B round on May 16, 2023, with participation from 17 investors. Its primary sector is Cell Therapy. In United States, the Cell Therapy sector has seen $349M in funding in 2026 to date.

Where does Ensoma rank among its competitors?

Ensoma ranks 64th amongst 664 active competitors, of which 228 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Ensoma?

Ensoma's top competitors include Alnylam, Spark Therapeutics and Strand Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Ensoma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of in vivo hematopoietic stem cell engineering for genomic medicine. The company’s technology platform enables in vivo engineering of hematopoietic stem cells. It combines an off-the-shelf in vivo delivery system with a gene engineering toolkit. The vision is for a hematopoietic stem cell engineering platform that selectively and durably modifies cells of the hematopoietic system with the intent to treat diseases with versatility. The aim is to shape a new patient experience defined by simplicity, speed and safety.

Website: ensoma.com
Social
Email ID: *****@ensoma.com
Registered Address: Boston (United States)

Key Metrics

Founded Year

2019

Location

Boston, United States

Stage

Series B

Total Funding

$205M in 3 rounds

Latest Funding Round

Series B, May 16, 2023, $*****

Investors

5AM Ventures & 19 more

Ranked

64^th among 664 active competitors

Employee Count

57 as on Apr 30, 2026

Investment & Acquisitions

Twelve Bio

Similar Companies

Alnylam & 832 more

View Ensoma's full profile

Ensoma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ensoma, Inc. CIN: 84-2970518 , United States, Active	Dec 31, 2018	-	52 (As on Dec 31, 2021)	-

Ensoma has raised a total funding of $205M over 3 rounds. Its first funding round was on Feb 11, 2021. Its latest funding round was a Series B round on May 16, 2023 for $*****. 17 investors participated in its latest round. Ensoma has 20 institutional investors.

Here is the list of recent funding rounds of Ensoma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 16, 2023	1917538	Series B	9621131	6578597	2024843	9975706
Jan 05, 2023	9587026	Series B	2403565	5255324	9961889	F-Prime Capital & 11 more
Feb 11, 2021	2874231	Series A	5194757	7113516	5AM Ventures	RIT Capital Partners & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Ensoma's funding rounds and investors

The founders of Ensoma are Andre Lieber and Hans Peter Kiem.

Here are the details of Ensoma's key team members:

Andre Lieber: Co-Founder of Ensoma.
Hans Peter Kiem: Co-Founder of Ensoma.
Kush Parmar: Co-Founder of Ensoma.

View details of Ensoma's Founder profiles and Board Members

Ensoma's employee count trend

Ensoma has 57 employees as of Apr 26. Here is Ensoma's employee count trend over the years:

Uncover Ensoma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ensoma include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of Ensoma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	71/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Healthcap, F-Prime Capital & 9 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Danforth Advisors, Frazier Life Sciences & 2 others	67/100
64th	Ensoma 2019, Boston (United States), Series B	Developer of in vivo hematopoietic stem cell engineering for genomic medicine	$205M	Qatar Investment Authority, Cormorant Asset Management ... & 18 others	58/100